Using genomic markers to predict skin cancer risk from UV damage
Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk
This study is looking at how special tests on your DNA can help figure out your risk of getting skin cancer from sun exposure, so that people who are more at risk can get better prevention and care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10808040 on NIH RePORTER |
What this research studies
This research investigates how genomic dosimeters can be used to assess an individual's risk of developing skin cancer due to UV exposure. By analyzing specific regions of DNA that are particularly sensitive to UV damage, researchers aim to create a more personalized approach to cancer prevention. The study employs advanced genomic techniques and a novel skin biopsy method to gather data on DNA damage, which will help identify high-risk individuals who may benefit from closer monitoring and preventive measures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of significant UV exposure or those with a family history of skin cancer.
Not a fit: Patients who have no history of UV exposure or skin cancer in their family may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective skin cancer prevention strategies tailored to individual risk profiles.
How similar studies have performed: Other research has shown promise in using genomic markers for cancer risk prediction, indicating that this approach could be a valuable advancement in precision medicine.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Brash, Douglas E — Yale University
- Study coordinator: Brash, Douglas E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.